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Increased glucose utilization by aldose reductase (AR)
has been implicated in the development of diabetes
complications. However, the mechanisms that regulate
AR during diabetes remain unknown. Herein we report
that several nitric oxide (NO) donors prevent ex vivo
synthesis of sorbitol in erythrocytes obtained from
diabetic or nondiabetic rats. Compared with erythro-
cytes of nondiabetic rats, the AR activity in the eryth-
rocytes of diabetic rats was less sensitive to inhibition
by NO donors or by AR inhibitors—sorbinil or tolrestat.
Treatment with N
G-nitro-L-arginine methyl ester (L-
NAME), an inhibitor of NO synthesis, enhanced AR
activity and sorbitol accumulation in tissues of nondia-
betic rats. Application of transdermal nitroglycerin
patches or treatment with L-arginine did not inhibit AR
activity or sorbitol accumulation in the tissues of non-
diabetic animals. Treatment with L-NAME increased,
whereas treatment with L-arginine or nitroglycerine
patches decreased AR activity and sorbitol content in
tissues of diabetic rats. These observations suggest that
NO maintains AR in an inactive state and that this
repression is relieved in diabetic tissues. Thus, in-
creasing NO availability may be a useful strategy for
inhibiting the polyol pathway and preventing the
development of diabetes complications. Diabetes 51:
3095–3101, 2002
A
ldose reductase (AR) is the ﬁrst and rate-
limiting enzyme of the polyol pathway (1).
Under euglycemic conditions, AR plays a minor
role in glucose metabolism; however, during
diabetes, its contribution is signiﬁcantly enhanced (1–3).
The increase in AR activity by hyperglycemia has been
proposed to be the underlying metabolic cause of second-
ary diabetes complications such as cataractogenesis, reti-
nopathy, neuropathy, and nephropathy (1–3). Because AR
utilizes NADPH, it has been suggested that the activation
of this enzyme depletes reducing equivalents, which may
be otherwise required for the detoxiﬁcation of oxidants
(3). An increase in AR activity also results in sorbitol
accumulation. This could potentially disrupt cellular integ-
rity and function by imposing osmotic stress. Therefore,
inhibiting AR could be useful in preventing oxidative and
osmotic changes that accompany the excessive metabo-
lism of glucose via the polyol pathway (2).
The etiological role of AR in diabetes complications is
supported by extensive evidence demonstrating that inhi-
bition of this enzyme prevents hyperglycemic changes in
the lens, kidney, and nerve (1–3). Nonetheless, in clinical
trials AR inhibitors have been found to be only moderately
effective, and issues related to their nonselectivity and
nonspeciﬁc toxicity have remained unresolved (4,5). In
addition, the efﬁcacy of these drugs in inhibiting AR during
diabetes may be compromised by changes in AR protein.
Previous studies have shown that AR isolated from dia-
betic or hyperglycemic tissues is less susceptible to inhi-
bition and is kinetically different from the enzyme puriﬁed
from normal or euglycemic human or animal tissues (6–8).
Similar changes in the inhibitor sensitivity and the kinetic
properties have been reported upon thiol oxidation of the
puriﬁed protein in vitro (9–11), suggesting that diabetic
changes in AR may be due to redox modiﬁcation of its
cysteine residues.
The high sensitivity of AR to oxidants has been attrib-
uted to the presence of a hyper-reactive cysteine residue
(Cys-298) located at the active site of the enzyme. Al-
though oxidation of Cys-298 does not abolish catalysis, it
decreases substrate and inhibitor binding (12–16). Our
recent studies show that this residue is particularly sensi-
tive to modiﬁcations by nitric oxide (NO) donors and could
be readily nitrosated or thiolated (17–19). The avidity with
which AR reacts with NO donors raises the possibility that
NO may be a physiological regulator of AR and therefore
the ﬂux of glucose through the polyol pathway. Further-
more, because diabetes is associated with a decrease in
NO bioavailablity (20,21), it is likely that the changes in AR
activity during diabetes may be secondary to the changes
in NO synthesis or availability. To test this view, we
examined the effects of increasing the synthesis and
availability of NO on the AR activity of nondiabetic and
diabetic tissues. Our results show that increasing NO
availability inhibits AR, whereas inhibiting NO synthesis
promotes the activation of the enzyme. These results
could form the basis of a new therapeutic approach for
treating diabetes complications with donors or precursors
of NO to inhibit AR and the activation of the polyol
pathway.
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Sprague Dawley rats (200–300 g) were housed in accor-
dance with institutional guidelines. Streptozotocin (STZ),
S-nitrosoglutathione (GSNO), 3-morpholinosydnonimine
(SIN-1), the protease inhibitor cocktail (4-[2-aminoethyl]
benzenesulfonyl ﬂuoride hydrochloride [AEBSF], leupep-
tin, bestatin, E-64, and pepstatin-A) were obtained from
Sigma Chemical. The NO donors, ()-S-nitroso-N-acetyl-
penicillamine (SNAP), diethylamine NONOate (NONOate),
and GSNO mono-ethyl ester (GSNO-ester), N
G-nitro-L-
arginine methyl ester (L-NAME), and L-arginine were pur-
chased from Calbiochem. Sorbinil and tolrestat were
obtained from Pﬁzer and American Home Products,
respectively. Deriva-Sil was purchased from Regis Tech-
nologies, and transdermal nitroglycerine patches were
obtained from Hercon Labs.
Diabetes was induced by a single intraperitoneal injec-
tion of STZ (65 mg/kg). Blood glucose was monitored
daily, and only the rats with blood glucose 400 mg/dl on
the 3rd day after the STZ injection were used for further
experiments. The rats were killed by injecting pentobarbi-
tal 6 days after the STZ injection (i.p.). Blood was collected
by cardiac puncture in heparinized tubes and washed
three times with PBS, pH 7.0. All animal protocols were
approved by the institutional animal care committee.
Erythrocytes (0.2 ml) from normal and hyperglycemic rats
were incubated with NO donor or AR inhibitors in 1.0 ml
of PBS containing 1 mmol/l EDTA and 5.5 mmol/l glucose.
The samples were incubated at 25°C in a shaking water
bath for 2 h. Wherever indicated, glucose was added to the
medium to a ﬁnal concentration of 40 mmol/l, and incuba-
tions were continued for another4ha t3 7 °C in a shaking
water bath. At the end of the incubation period, the
samples were centrifuged at 3,000g for 5 min, and the
pellet was washed three times with PBS. The cells were
lysed by adding 0.4 ml water, and the proteins were
precipitated by adding 0.4 ml each of 0.15 mol/l Ba(OH)2
and 0.15 mol/l ZnSO4. The precipitate was removed by
centrifugation at 10,000g for 5 min. The supernatant was
ultraﬁltered through a YM-10 Microcon (Millipore) by
centrifugation at 10,000g. An aliquot of the ﬁltrate was
lyophilized in a SpeedVac to complete dryness and stored
in a vacuum dessicator containing calcium chloride for at
least 24 h.
To measure sorbitol content, the dried samples were
derivatized by adding 0.1 ml of the Deriva-Sil solvent under
anhydrous conditions. The derivatized mixture (1 l) was
injected into a Varian Gas Chromatograph (GC system
3,000) equipped with hydrogen ﬂame ionization detector
and Chromopack capillary column packed with CP Sil
24CB. The column temperature was set at 140°C, and the
temperature gradient was set from 140°Ct o1 7 0 °C increas-
ing 4°C per min and from 170°Ct o2 5 0 °C and then 50°C per
min. The column was maintained at this temperature for
an additional 3 min. The injection port was maintained at
250°C, and the detector temperature was set at 300°C. The
amount of sorbitol present in the sample was calculated
using reagent sorbitol measured by gas chromatography
under similar conditions. The sorbitol peak was conﬁrmed
by mass spectrometry.
The L-arginine analog L-NAME was used to inhibit NO
synthesis (22) in a dose range shown to be effective in rats
(50 mg  kg
–1  day
–1, i.p.) (23). The synthesis of NO was
enhanced treating rats with L-arginine (200 mg  kg
–1 
day
–1, i.p.), which is a substrate of NO synthase (22), and
has been shown to increase NO generation in vivo (24).
Additionally, nitroglycerine patches, which release 200 ng
of NO per min (25), were applied on the preshaved dorsal
neck region of the rats. The nitroglycerine patches were
replaced everyday. After 10 days of treatment, the rats
were killed and several tissues (lung, heart, liver, kidney,
testis, sciatic nerve, skeletal muscle, and brain) were
harvested and their erythrocytes collected. The tissues
were homogenized in 1.0 ml ice-cold PBS containing 20 l
protease inhibitor cocktail. The AR activity and sorbitol
content of the homogenates were measured. In a separate
series of experiments, erythrocytes from normal or dia-
betic rats were incubated with 40 mmol/l glucose in PBS at
37°C for 6 h before measuring AR activity and sorbitol.
Data are presented as the means  SE. Data were analyzed
with unpaired Student’s t test using Excel spreadsheets.
RESULTS
Sorbitol accumulation in erythrocytes from normal
and diabetic rats. Erythrocytes were isolated from nor-
mal rats and were incubated with 5.5 or 40 mmol/l glucose.
After 4 h, the sorbitol levels in these cells were 0.024 
0.004 and 0.18  0.013 nmol/mg protein, respectively.
When the erythrocytes isolated from diabetic rats were
incubated with 40 mmol/l glucose, their sorbitol content
was found to be 0.41  0.04 nmol/mg protein, which was
twofold higher than the sorbitol content of the erythro-
cytes from similarly treated nondiabetic rats. These results
indicate that even at the same concentration of extracel-
lular glucose, the diabetic cells accumulate more sorbitol
than nondiabetic cells, which may be in part due to the
upregulation of AR during diabetes. To examine whether
sorbitol accumulation in these cells was due to AR, the
erythrocytes were incubated with glucose in the presence
of the AR inhibitors sorbinil or tolrestat (1 mmol/l each).
As shown in Table 1, both these inhibitors prevented,
nearly completely, the accumulation of sorbitol, indicating
that erythrocyte sorbitol is derived entirely from the
AR-catalyzed reduction of glucose and that the sorbitol
content is a valid surrogate measure of cumulative AR
catalysis in these cells. Interestingly, the formation of
sorbitol in diabetic erythrocytes was less affected by
sorbinil and tolrestat (77–84% inhibition) compared with
the cells isolated from nondiabetic animals, in which
97–98% inhibition of sorbitol synthesis was observed with
these inhibitors (Fig. 1). These data are consistent with
our work showing that diabetes diminishes the inhibitor
sensitivity of AR (6–8).
Regulation of erythrocyte sorbitol synthesis by NO
donors. To determine whether NO could inhibit AR
activity and prevent sorbitol synthesis in erythrocytes, we
used NO donors, which provide more uniform steady-state
levels of NO than NO gas itself (26). Erythrocytes isolated
from both normal and diabetic rats were incubated with
several NO donors to rule out donor-speciﬁc effects and to
compare relative efﬁcacies. All the donors examined (at 1
mmol/l each) prevented sorbitol accumulation to nearly
the same extent (70–86%) (Table 1), although SNAP was
found to be the most effective compound of this series.
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appears likely that this inhibition is related to NO and is
not unique to the chemical nature of the donor molecule.
The NO donors also inhibited sorbitol accumulation in
diabetic erythrocytes (Fig. 1); however, as compared with
normal cells, the extent of inhibition of sorbitol accumu-
lation in the diabetic erythrocytes was much less (28–58%
vs. 70–86% inhibition). The difference between the two
groups was statistically signiﬁcant (P  0.01). It is note-
worthy that the sorbitol content of erythrocytes from
diabetic rats incubated with 40 mmol/l glucose and sorbi-
nil or tolrestat was 11- or 33-fold higher than that of the
erythrocytes from normal rats incubated with the AR
inhibitors under identical conditions, suggesting that even
a small fraction of AR remaining uninhibited during dia-
betes could result in profound sorbitol accumulation.
Together, these observations suggest that NO inhibits AR
activity and prevents sorbitol accumulation in normal as
well as diabetic erythrocytes. As with sorbinil and tolres-
tat, the higher resistance of AR in diabetic cells to inhibi-
tion by NO donors may be reﬂective of diabetic changes in
the AR protein.
Regulation of tissue AR activity and sorbitol accumu-
lation by NO. To investigate the in vivo effects of NO,
nondiabetic and diabetic rats were treated either with the
NO synthase (NOS) substrate, L-arginine, or the NOS
inhibitor, L-NAME (27,28). In addition, we also examined
the consequences of delivering NO via a transdermal
nitroglycerine patch, which releases NO slowly into the
circulation (25). Eight groups of rats were examined:
groups I–IV were euglycemic and groups V–VIII were
made diabetic by a single injection of STZ. Group I
received no treatment, while group II was treated with
L-NAME, group III with the nitroglycerine patch, and group
IV with L-arginine. Group V received no treatment. Groups
VI, VII, and VIII were treated with L-NAME, nitroglycerine
patch, and L-arginine, respectively. Ten days after diabetes
and/or the indicated treatments, the rats were killed. Their
blood was collected and their tissues harvested. As shown
in Table 2, measurable levels of AR activity and sorbitol
were present in several tissues and organs. The highest AR
activity was observed in the sciatic nerve followed by lung,
brain, muscle, kidney, and heart (in descending order).
The pattern of relative tissue distribution of AR is similar
to that reported before (1). Detectable amounts of sorbitol
were recovered from the tissues that expressed AR, and in
general the sorbitol content reﬂected the tissue AR activ-
ity. Among the tissues examined, the highest sorbitol
content was detected in sciatic nerve, followed by lungs,
brain, and skeletal muscle.
Treatment of nondiabetic rats with L-NAME led to an
increase in AR activity and sorbitol accumulation (Table
2). The highest increase in sorbitol activity was observed
in sciatic nerve (threefold), followed by kidney (1.7-fold),
brain (1.6-fold), skeletal muscle (1.6-fold), and heart (1.4-
fold), suggesting that endogenous generation of NO in
these tissues maintains AR in the repressed state, which is
relieved upon inhibiting NO synthesis. The repressing
effect of NO was also observed on AR activity, and
treatment with L-NAME led to a sixfold increase in the
enzyme activity in the lungs, a 5.2-fold increase in the
FIG. 1. NO donors inhibit sorbitol accumulation in erythrocytes.
Erythrocytes were isolated from nondiabetic and diabetic rats and
incubated with 40 mmol/l glucose and the indicated additives. Eryth-
rocytes from both normal and diabetic rats were incubated with 5.5
mmol/l glucose without or with the indicated additives at 1 mmol/l each
f o r2ha t2 5 °C. Subsequently, additional glucose was added to the
medium to a ﬁnal concentration to 40 mmol/l, and the mixture was
incubated for an additional4ha t37°C. The percentage of decrease in
sorbitol content of erythrocytes from diabetic rats was calculated by
comparing with the extent of sorbitol accumulation in the absence of
the additive (100%). The sorbitol content was determined by gas
chromatography as described in the text. The data are means  SE (n 
6). In all cases the difference between diabetic and nondiabetic tissues
was statistically signiﬁcant (P < 0.05).
TABLE 1
NO donors prevent sorbitol formation in erythrocytes isolated from nondiabetic and diabetic rats
Additive
Nondiabetic Diabetic
Sorbitol (nmol/mg protein) Inhibition (%) Sorbitol (nmol/mg protein) Inhibition (%)
None 0.180  0.013 0 0.41  0.042 0
Sorbinil 0.006  0.001 96.7  2.3 0.064  0.008 84.4  3.2*
Tolrestat 0.003  0.001 98.4  1.06 0.094  0.005 77.1  8.5*
SNAP 0.025  0.007 86.2  4.9 0.171  0.007 58.3  4.5*
GSNO 0.054  0.009 70.0  2.3 0.176  0.008 57.08  3.8*
GSNO-ester 0.050  0.006 72.23  3.4 0.260  0.009 36.6  12.0†
SIN-1 0.044  0.003 75.56  4.6 0.296  0.003 27.81  6.9†
NONOate 0.05  0.005 72.23  4.3 NE NE
Data are means  SEM (n  6). Erythrocytes obtained from nondiabetic or diabetic rats were incubated with 40 mmol glucose without or
with the indicated additives for6ha sdescribed in the text. The sorbitol content was determined by gas chromatography. All additives were
added to a ﬁnal concentration of 1 mmol/l. Percent inhibition was calculated using the sorbitol concentration of the erythrocytes determined
without any additives (row labeled “none”). *P  0.01, †P  0.001. NE, not examined.
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However, when the rats were treated with either the
nitroglycerin patch (group III) or L-arginine (group IV), no
signiﬁcant inhibition of AR activity or sorbitol accumula-
tion was observed, indicating that the NO regulation of the
polyol pathway in nondiabetic rats is maximal and cannot
be enhanced further by exogenous delivery of NO.
As expected, tissues removed from diabetic rats (group
V) displayed higher sorbitol content and AR activity. As
with untreated nondiabetic controls, the highest level of
sorbitol in the diabetic rats was found in sciatic nerve
(2,499  253 nmol/mg protein) followed by lung, heart,
brain, muscle, and kidney in the range of 17–59 nmol/mg
protein. Trace levels of sorbitol were observed in liver and
testis (Table 3). Treatment of diabetic rats with L-NAME
(group VI) resulted in a 2- to 3.8-fold increase in the
sorbitol content of all tissues examined compared with
untreated diabetic rats (group V): 382, 297, 286, and 275%
increase in brain, heart, lung, and testes, respectively. The
increase in sorbitol accumulation was accompanied by a
corresponding increase in AR activity.
Treatment of diabetic rats with agents that enhance NO
levels (nitroglycerine patch or L-arginine) uniformly led to
an inhibition of AR activity and sorbitol accumulation. As
shown in Table 3, in the tissues isolated from L-arginine-
treated rats (group VIII), the decrease in sorbitol content
was maximum in heart (94%), followed by brain (90%),
testis (89%), erythrocytes (89%), kidney (84%), and sciatic
nerve (80%) compared with untreated diabetic rats (group
V). Treatment with nitroglycerine patch (group VII) also
had an inhibitory effect on sorbitol content and AR activ-
ity. The decrease in sorbitol content in tissues from group
VII rats compared with group V rats was most prominent
in heart (68%) followed by sciatic nerve (67%) and eryth-
rocytes (62%).
Reversibility of NO-mediated changes. To determine
whether the inhibition of AR by NO is reversible, erythro-
cytes isolated from group I –VIII rats were incubated ex
TABLE 2
Regulation of aldose reductase activity and sorbitol levels by NO in nondiabetic rats
Tissue
Group I: no treatment Group II: L-NAME Group III: NG patch Group IV: L-arginine
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Heart 1.68  0.57 0.42  0.057 2.45  0.41* 2.19  0.036† 1.57  0.036 0.398  0.021 1.58  0.37 0.41  0.017
Kidney 0.7  0.041 0.45  0.036 1.2  0.013* 0.94  0.051* 0.654  0.032 0.446  0.005 0.71  0.33 0.42  0.01
Lungs 5.1  0.76 1.28  0.09 6.98  0.047† 7.67  0.57† 4.67  0.047 1.21  0.01 4.91  0.03 1.19  0.006
RBC 0.02  0.005 ND 0.023  0.003 0.011  0.002 0.02  0.003 ND 0.0178  0.008 ND
Brain 0.87  0.057 1.098  0.065 1.4  0.05* 1.19  0.007 0.79  0.007 1.071  0.009 0.81  0.023 0.99  0.045
Muscle 1.1  0.078 1.098  0.043 1.78  0.01* 1.43  0.008* 1.045  0.009 0.987  0.007 0.95  0.014 1.01  0.004
Liver ND ND ND 0.008  0.0021 ND ND ND ND
Testis ND ND 0.04  0.005 ND ND ND ND ND
Sciatic nerve 189.9  23.3 20.78  1.03 567.7  21.45† 26.34  1.79 178.8  6.78 16.87  1.08 183  5.43 18.2  0.85
Data are means  SEM (n  5). Male Sprague Dawley rats were either left untreated (group I) or were treated with L-NAME (50 mg/kg; i.p.;
group II), nitroglycerine (NG) patch (group III), or L-arginine (200 mg/kg; i.p.; group IV). The NG patch was applied to the shaved dorsal neck
region of group III rats. The NG patch was changed every day. After 10 days, group I–IV rats were killed, and the indicated tissues were
harvested. In the tissue extracts, the sorbitol content was determined by gas chromatography, and the AR activity was determined
spectrophotometrically using DL-glyceraldehyde as the substrate. The AR and sorbitol levels were normalized to the total protein in the
extract. *P  0.01 and †P  0.001 compared with group 1. ND, not detectable.
TABLE 3
Regulation of aldose reductase activity and sorbitol levels by NO in diabetic rats
Tissue
Group V: no treatment Group VI: L-NAME Group VII: NG patch Group VIII: L-arginine
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Sorbitol
(nmol/mg
protein)
AR
(mU/mg
protein)
Heart 26.8  4.57 9.42  0.57 79.8  16.9* 19.2  3.86* 8.49  0.56* 4.34  0.32* 1.52  0.37* 1.67  0.2*
Kidney 17  2.41 7.05  0.62 37.4  13.4* 16.4  2.3† 7.16  0.52* 3.69  0.37† 2.6  0.33* 1.16  0.28*
Lungs 59.1  4.26 19.8  2.08 169  31.2* 41.6  4.63† 30.5  2.19† 7.88  1.12† 13.6  3.71* 4.85  1.09*
RBC 0.29  0.02 1.23  0.12 0.71  0.12* 2.86  0.42† 0.11  0.01* 0.49  0.09* 0.03  0.01* 0.21  0.02*
Brain 22  3.57 17.2  1.05 84.1  19.6* 41.5  5.03* 12.2  1.75† 7.73  1.8† 2.1  0.48* 4.69  0.54*
Muscle 18.2  1.8 18.7  1.33 41.9  9.2† 33.7  3.58† 12.1  1.87† 5.28  0.39* 7.65  1.0† 6.26  0.66*
Liver 0.23  0.05 4.04  0.48 0.34  0.08† 5.47  0.55† 0.1  0.01† 1.22  0.19* 0.06  0.01* 1.59  0.2*
Testis 1.36  0.13 6.46  0.77 3.74  0.91* 17.8  2.79† 0.97  0.06† 2.09  0.16* 0.14  0.04* 1.33  0.17*
Sciatic nerve 2499  253 278  10.9 4857  283† 568  25.1† 805  75.6* 188  13.4† 490  38.5* 130  7.59†
Data are mean  SEM. Male Sprague Dawley rats were made diabetic by a single injection of STZ (65 mg/kg; i.p.). Group V rats were left
untreated, whereas group VI and VII rats were treated every day for 10 days with L-NAME (50 mg/kg; i.p.) or L-arginine (200 mg/kg; i.p.),
respectively. The nitroglycerine (NG) patch was applied to the shaved dorsal neck region of group VII rats. The NG patch was changed every
day. After 10 days, group V–VIII rats were euthanized and the indicated tissues were harvested. The sorbitol content of the tissue extracts
was determined by gas chromatography, and the AR activity was measured spectrophotometrically using DL-glyceraldehyde as the substrate.
(n  5). *P  0.001 and †P  0.01 compared with group V.
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and the sorbitol content were determined. In case of
erythrocytes from nondiabetic rats (groups I–IV), the basal
levels of AR activity and sorbitol were below the detection
limit of our assays. However, after6ho fincubation with
40 mmol/l glucose, both the AR activity and the sorbitol
content increased dramatically but were comparable
among groups I–IV (data not shown). In case of diabetic
rats (groups V–VIII), the AR activity and sorbitol content in
erythrocytes isolated from L-NAME–treated animals were
more than twofold higher and those from L-arginine and
nitroglycerine patch–treated animals were inhibited 80
and 60%, respectively as compared with untreated diabetic
controls (group V). The differences between the groups
were signiﬁcantly diminished after6ho fincubation (Fig.
2), indicating that the stimulatory or inhibitory effects of
NO on AR are reversible and that once NO-generation is
normalized, AR activity and sorbitol synthesis revert back
to their basal levels.
DISCUSSION
Increased activity of AR and the polyol pathway has been
suggested to be the underlying biochemical cause of
secondary diabetes complications (1–3). The role of AR in
the pathogenesis of diabetes complications is supported
by extensive evidence showing that inhibition of the
enzyme prevents and/or delays the development of dia-
betic cataracts, neuropathy, or nephropathy (1–3). How-
ever, in cell culture studies, hyperglycemia induces
progressive resistance of the enzyme to inhibition (29),
and AR isolated from diabetic humans or animals is more
resistant to pharmacological inhibition than that from
normal, euglycemic tissues (6–8). Moreover, in clinical
trials, AR inhibitors display high nonspeciﬁc toxicity and
low efﬁcacy (4,5), suggesting that our understanding of the
enzyme and its regulation during diabetes is incomplete
and that additional investigations are required to rationally
redesign anti-AR interventions.
Our in vitro studies show that due to the presence of an
active site cysteine (cys-298), AR is very sensitive to
oxidants (12,13,15). Several thiol-modifying reagents alter
AR catalysis and substrate and inhibitor binding, suggest-
ing that in vivo the enzyme may be under redox regulation.
Although thiol-disulﬁde regulation may represent one such
mechanism (30), recent evidence suggests that the multi-
potent regulator, NO, which controls several diverse func-
tions, could initiate and participate in a number of redox
reactions, including nitrosation, nitration, and S-thiolation
(31–33). Indeed, our studies show that exposure to NO
donors results in rapid and selective modiﬁcation of AR at
cys-298 (17–19). These observations suggest that NO may
be a physiological regulator of AR activity in vivo and that
changes in NO availability during diabetes could alter AR
catalysis and consequently the polyol pathway activity. In
agreement with this, the present studies show that NO
donors inhibit AR activity and sorbitol accumulation in
erythrocytes. These observations are consistent with the
view that NO is a physiological regulator of AR. In the in
vitro studies, NO donors induce a variety of changes in AR
catalysis, and substrate and inhibitor binding (17–19). The
NO-releasing agents, such as SNAP or NONOate, cause
nitrosation of AR protein, and the nitrosated enzyme is
more active and more resistant to inhibitors than the
native form (19). In contrast, nitrosothiols such as GSNO
and SNAP inhibit AR by S-thiolating cys-298 (18). Hence,
depending on the nature of the NO donor, AR could be
either nitrosated or thiolated and activated or inhibited.
However, in glutathione-proﬁcient cells, the paracrine
effects of NO are likely to be mediated by nitrosothiols
(32,33). Hence, the predominant form of AR modiﬁcation
induced in these cells is likely to be glutathiolation, which
will lead to enzyme inactivation. Indeed, all of the NO
donors examined in the present study inhibited AR (Table
1), suggesting that under euglycemic conditions, NO inhib-
its rather than activates AR catalysis in vivo.
The inhibitory effect of NO on AR catalysis and the
polyol pathway activity was also evident in diabetes. The
erythrocytes of diabetic animals when incubated with
glucose ex vivo or tissues isolated from diabetic rats
accumulated signiﬁcantly less sorbitol when treated with
NO donors. However, the extent of inhibition of sorbitol
formation in the diabetic erythrocytes was much less than
that observed in normal, euglycemic cells, indicating that
diabetes increases the inhibitor resistance of AR. Although
the speciﬁc modiﬁcations of the AR protein remain un-
identiﬁed, we speculate that under glutathione-replete
conditions NO S-thiolates AR. However, during hypergly-
cemia NO availability is diminished, and because of a
concurrent loss of glutathione, the residual NO (instead of
S-thiolating) causes nitrosation of AR. Although specula-
tive, this view accounts for the inhibitor resistance of AR
and for the increased sorbitol accumulation in diabetic
tissues.
In addition to post-translational changes in AR protein,
NO could also affect the transcription of the AR gene. It
has been shown that stimulation of vascular smooth
muscle cells in culture with NO donors results in an
increase in AR mRNA and activity and that inhibiting NO
synthesis prevents the increase in AR in lipopolysaccha-
ride or interferon-–stimulated macrophages (34). Al-
though the in vivo signiﬁcance of these results remains to
be established, they suggest that the expression of AR
should increase with an increase in NO generation or
FIG. 2. Reversibility of NO-induced AR modiﬁcation. The AR activity
and the sorbitol content of erythrocytes isolated from diabetic rats
that were untreated (group V) or treated with L-NAME (group VI),
L-arginine (group VIII), or nitroglycerine (NG) patch (group VII) was
determined before 0 and after6ho fe xvivo incubation with 40 mmol/l
glucose at 37°C. The data are means  SE (n  5). There was no
statistical difference between the values of either AR activity or
sorbitol content between the four groups after6ho fincubation.
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not increase AR activity (Tables 2 and 3) suggests that the
transcriptional activation of the AR gene in vivo by NO is
marginal or that this effect is overcome by the post-
translational inhibition of AR activity. Nevertheless, the
regulation of the AR gene by other stimuli could not be
ruled out. The AR gene is stimulated by the tonicity of high
glucose (35,36), as well as growth factors, mitogens (37),
cytokines (38), and oxidants (37,39). Many of these stimuli
are affected by diabetes and could change AR expression
during diabetes. However, our observation that NO donors
acutely inhibit AR activity in erythrocytes provides strong
evidence supporting a post-translational mechanism. And
collectively, our results are consistent with the view that
NO represses, rather than activates, AR and that AR is
stimulated by a lack of NO, resulting in an increase in the
polyol pathway activity. During diabetes NO availability is
decreased (even though the NO synthesis per se may be
enhanced), and therefore the net effect will be further
de-repression of AR and stimulation of sorbitol synthesis.
The de-repression of AR due to loss of NO is supported
by our data showing that treatment with L-NAME, which
inhibits NO synthesis, caused a considerable increase in
AR activity and sorbitol formation in nondiabetic as well
as the diabetic tissues (Tables 2 and 3). These results
suggest that a signiﬁcant fraction of AR remains inhibited
by NO, and if this inhibition is removed AR is activated.
Fundamentally, these data demonstrate that AR activity,
or more importantly the ﬂux of glucose through the polyol
pathway leading to NADPH depletion and sorbitol accu-
mulation, is not a simple function of extracellular glucose
concentration. Under euglycemic conditions NO represses
AR by maintaining the enzyme in an inactive, S-thiolated
state; however, during diabetes NO availability is reduced
and the enzyme is liberated from this repression (40).
Previous studies have shown that under euglycemic
conditions the polyol pathway activity represents 3% of
the total glucose ﬂux. However, during hyperglycemia,
metabolism via AR accounts for 30% of the total glucose
utilized (41). This increase could be due to a simple mass
effect; at low glucose concentrations low levels of sorbitol
are synthesized, whereas high glucose leads to higher
polyol pathway activity. Any nonlinearity in the response
could be accounted for by the low afﬁnity of AR for
glucose. Because AR has a high Km glucose, the ﬂux
through the polyol pathway will be signiﬁcant only at high
glucose concentration (1). Although our results do not
invalidate these considerations, they indicate that regula-
tion by NO imparts another level of complexity to the
relationship between glucose concentration and AR catal-
ysis, such that even at the same concentration of the
extracellular glucose, the level of AR catalysis as well as
the ﬂux of glucose through the polyol pathway could
change depending on the availability of NO.
Our results with L-arginine and the nitroglycerine patch
show that under euglycemic conditions exogenous deliv-
ery of NO does not inhibit basal AR activity or sorbitol
accumulation. We suggest that in normal rats, the inhibi-
tion of AR by NO is maintained at a set level, which could
not be exceeded by exogenous application of NO-donors.
However, the observation that AR inhibition upon treat-
ment of diabetic animals with L-arginine or nitroglycerine
patches suggests that during diabetes there is partial
inhibition of AR by NO, which could be signiﬁcantly
enhanced by delivering NO or increasing the endogenous
synthesis of NO. Nonetheless, the effects of NO on other
processes, such as the regulation of AR expression (34),
sorbitol dehydrogenase, sorbitol efﬂux, and glucose avail-
ability and metabolism, cannot be completely ruled out
and are currently under investigation in our laboratory.
Regardless of the mechanism, our results suggest a new
approach for speciﬁcally inhibiting AR during diabetes. As
evident from Table 3, treatment with either the nitroglyc-
erine patch or L-arginine inhibited AR and prevented
sorbitol accumulation in diabetic animals, however, no
signiﬁcant effect of these interventions was observed in
nondiabetic animals (Table 2), demonstrating that the
inhibitory effects of NO appear to be speciﬁc to hypergly-
cemia and NO-donors do not perturb AR under euglyce-
mia. Moreover, in addition to inhibiting the polyol
pathway, enhancing NO during diabetes may provide
additional beneﬁts, such as restoration of endothelial
function and blood pressure (42–44). Therefore, NO ther-
apy may be useful in simultaneously preventing and treat-
ing several aspects of vascular pathology associated with
long-term diabetes.
In summary, the results of the present study demon-
strate for the ﬁrst time that endogenous NO maintains AR
in a partially inhibited state in vivo and prevents AR-
dependent accumulation of sorbitol in cells exposed to
high glucose. These observations provide a critical link
between our previous work showing on one hand that the
kinetic and the ligand binding properties of AR are highly
sensitive to thiol oxidation (9,10,12,13,15) and NO (17–19)
and on the other hand that these properties of the enzyme
are dramatically affected by diabetes (6–8). On the basis
of the current investigations, we propose that the changes
in AR associated with diabetes are due to perturbations in
the regulation of this enzyme by NO. During euglycemia,
AR is partially inhibited by nitrosothiols, whereas in
diabetes, AR is activated, presumably by nitrosation
and/or the loss of NO-mediated repression. This increase
in AR activity could be prevented by exogenous delivery of
NO or by enhancing NO synthesis. Thus, treatment with
nitroglycerine patch or L-arginine may be useful therapeu-
tic approaches for controlling or preventing diabetes com-
plications.
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